# EDGAR Filing Document

**Accession Number:** 0001962738
**File Stem:** 0001104659-26-012391
**Filing Date:** 2026-2
**Character Count:** 5707
**Document Hash:** 3b56a4b7097dfa8176e4446732413389
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-012391.hdr.sgml**: 20260210

**ACCESSION NUMBER**: 0001104659-26-012391

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260210

**FILED AS OF DATE**: 20260210

**DATE AS OF CHANGE**: 20260210

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CASI Pharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0001962738
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41666
- **FILM NUMBER:** 26613708

**BUSINESS ADDRESS:**
- **STREET 1:** 1701-1702, CHINA CENTRAL OFFICE TOWER 1
- **STREET 2:** NO. 81 JIANGUO ROAD, CHAOYANG DISTRICT
- **CITY:** BEIJING
- **STATE:** F4
- **ZIP:** 100025
- **BUSINESS PHONE:** 86 10 6561 8789

**MAIL ADDRESS:**
- **STREET 1:** 1701-1702, CHINA CENTRAL OFFICE TOWER 1
- **STREET 2:** NO. 81 JIANGUO ROAD, CHAOYANG DISTRICT
- **CITY:** BEIJING
- **STATE:** F4
- **ZIP:** 100025

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CASI Pharmaceuticals Holdings, Inc.
- **DATE OF NAME CHANGE:** 20230118

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE<br> 13a-16 OR 15d-16 UNDER<br> THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of February, 2026**

**Commission File Number 001-41666**

**CASI PHARMACEUTICALS, INC.**

(Translation of registrant's name into English)

**1701-1702, China Central Office Tower 1**

**No. 81 Jianguo Road, Chaoyang District**

**Beijing, 100025**

**People's Republic of China**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ⌧ Form 40-F ◻

**INCORPORATION BY REFERENCE**

The information included in this Report on Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form F-3 (File No. [333-283998](https://www.sec.gov/Archives/edgar/data/1962738/000110465924130920/tm2431074d1_f3.htm) and No. [333-281621](https://www.sec.gov/Archives/edgar/data/1962738/000110465924090555/tm2420556d1_f3.htm)) (including any prospectuses forming a part of such registration statement) and is to be a part thereof from the date on which this Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

**CASI Pharmaceuticals Reports the Receipt of Drug Registration Certificate for Thiotepa in China**

CASI Pharmaceuticals, Inc. (NASDAQ: CASI, the "Company"), a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases, today reported that CASI Pharmaceuticals (China) Co., Ltd. received the Drug Registration Certificate from National Medical Products Administration for Thiotepa for Injection. Such certificate shall remain valid till February 1, 2031.

The Company has exclusive distribution rights for Thiotepa in China from ESTEVE Pharmaceuticals GmbH (formerly known as RIEMSER Pharma GmbH). Please refer to the Company's earlier public disclosure with respect to the contemplated disposal of all licensing rights, distribution rights, supply arrangements and related rights related to Thiotepa (in China excluding Hong Kong, Macau and Taiwan) and certain other pipeline products to Kaixin Pharmaceuticals Inc..

**Forward-Looking Statements**

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as the Company's strategic and operational plans, contain forward-looking statements. The Company may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the "SEC"), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided herein is as of the date of this announcement, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. We caution readers not to place undue reliance on any forward-looking statements contained herein.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CASI Pharmaceuticals, Inc.** | **CASI Pharmaceuticals, Inc.** |
|  | By: | /s/ David Cory |
|  | Name: | David Cory |
|  | Title: | CEO |
| Date: February 10, 2026 |  |  |

---